Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3–internal tandem duplications in the QuANTUM-First trialRichard F. Schlenk, Harry P. Erba, Pau Montesinos et al.|Haematologica|2025Cited by 7
<i>FLT3</i> -ITD measurable residual disease from the QuANTUM-First trialMark J. Levis, Alexander E. Perl, Harry P. Erba et al.|Blood Advances|2025Cited by 7
Quantum-First Trial: FMS-like Tyrosine Kinase 3-Internal Tandem Duplication ( <i>FLT3</i>-ITD)-Specific Measurable Residual Disease (MRD) Clearance Assessed through Induction (IND) and Consolidation (CONS) Is Associated with Improved Overall Survival (OS) in Newly Diagnosed (nd) <i>FLT3</i>-ITD+ AML Patients (pts)Alexander E. Perl, Mark J. Levis, Harry P. Erba et al.|Blood|2023Cited by 5
Quantum-First: Effects of Quizartinib (Q) on RFS, OS, CIR, and MRD in Newly Diagnosed (nd) Patients (pts) with FMS-like Tyrosine Kinase 3-Internal Tandem Duplication-Positive (<i>FLT3</i>-ITD+) Acute Myeloid Leukemia (AML) Who Received Continuation (CONT) Therapy (tx)Mark J. Levis, Kristy Burns, Harry P. Erba et al.|Blood|2024Cited by 5
Correlation of Baseline Gene Mutations With Quizartinib Efficacy in Patients With <i>FLT3</i>-ITD-Positive Newly Diagnosed Acute Myeloid Leukemia in the Phase 3 QuANTUM-First TrialMark J. Levis, Harry P. Erba, Pau Montesinos et al.|Blood|2024Cited by 2